TOPICS

Category: Psoriasis

Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential

 J Clin Aesthet Dermatol. 2019;12(1):11–15 by James Q. Del Rosso, DO; Leon Kircik, MD; Tina Lin PharmD; and Radhakrishnan Pillai, PhD Dr. Del Rosso is with JDR Dermatology Research/Thomas Dermatology in Las Vegas, Nevada. Dr. Kircik is with the Indiana University School of Medicine in Indianapolis, Indiana; Physicians Skin Care, PLLC in Louisville, Kentucky; and

CONTINUE READING »

Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% Cream

 J Clin Aesthet Dermatol. 2018;11(11):15–19 by Neal D. Bhatia, MD; David M. Pariser, MD; Leon Kircik, MD; Tina Lin, PharmD; Susan Harris, MS; Lindsey Mathew; and Radhakrishnan Pillai, PhD Dr. Bhatia is with Therapeutics Clinical Research in San Diego, California. Dr. Pariser is with Virginia Clinical Research, Inc. in Norfolk, Vriginia. Dr. Kircik is with

CONTINUE READING »

A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis

by Olabola Awosika MD, MS; Misty G. Eleryan MD; Monica Rengifo-Pardo MD; Lindsay Doherty MS; Lisa W. Martin, MD; and Alison Ehrlich MD, MHS Drs. Awosika, Rengifo-Pardo, and Ehrlich are with the Department of Dermatology, The George Washington Medical Faculty Associates in Washington, DC. Dr. Martin is with the Department of Cardiology, The George Washington Medical

CONTINUE READING »